CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Assessment of ventilator-associated pneumonia criteriaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D053717 Pneumonia, Ventilator-Associated NIH 0.35
D011014 Pneumonia NIH 0.07
D045169 Severe Acute Respiratory Syndrome NIH 0.06
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients

The aim of this study is to determine the risk factors for development of ventilator-associated pneumonia (VAP) and to identify the prognostic factors of VAP among Coronavirus Disease 2019 (CoViD-19) patients. We hypothesized that CoViD-19 serves as a high risk factor for the development of VAP and it affects clinical outcome measures negatively.

NCT04372576 Ventilator Associated Pneumonia Corona Virus Infection Diagnostic Test: Assessment of ventilator-associated pneumonia criteria
MeSH:Pneumonia, Ventilator-Associated Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia

Primary Outcomes

Measure: 28-day all-cause mortality

Time: at study completion, anticipated 5 months

Secondary Outcomes

Measure: Days of mechanical ventilation

Time: average time frame expected 2-3 weeks

Measure: ICU length-of-stay

Time: average time frame expected 3-4 weeks

Measure: Antibiotic utilization

Time: average time frame expected 3-4 weeks (at discharge from ICU)

Measure: Ventilator-associated pneumonia rate

Time: at study completion, anticipated 5 months

Related HPO nodes (Using clinical trials)